Sotac Pharmaceuticals

Sotac Pharmaceuticals Receivables

The Accounts Receivable of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 26, 2026 is 341.12 M INR. In the previous year, Accounts Receivable was 122.53 M INR — a change of 178.40% (higher).

Receivables

341.12 MINR

YoY

178.40%

Last updated:

Accounts Receivable of Sotac Pharmaceuticals is 2025 341.12 M INR. Accounts Receivable of Sotac Pharmaceuticals was 2024 122.53 M INR. It decreases by 178.40% higher compared to the previous year.

The Sotac Pharmaceuticals Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2020
69.60 M INR
Jan 1, 2021
58.85 M INR
Jan 1, 2022
122.53 M INR
Jan 1, 2025
341.12 M INR
The Sotac Pharmaceuticals Receivables history
YEARReceivablesYoY
341.12 MINR+178.40%
122.53 MINR+108.23%
58.85 MINR-15.46%
69.60 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

Accounts Receivable of Sotac Pharmaceuticals is 341.12 M INR in 2025.

Accounts Receivable of Sotac Pharmaceuticals changed from 122.53 M INR to 341.12 M INR, representing a 178.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Sotac Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals